Serina Therapeutics, Inc. SER

Serina Therapeutics reported cohort 1 observations from its SER-252 registrational study in advanced Parkinson’s disease and advanced to cohort 2. Advancement of SER-252 registrational study in Parkinson’s disease signals major pipeline progress with direct effects on company trajectory.

Serina Therapeutics, Inc. has secured up to $20 million in funding to advance the registrational trial of its drug SER-252 for Parkinson’s disease. This financial support aims to facilitate the development and potential commercialization of the treatment, which targets unmet needs in the management of Parkinson’s disease symptoms. Securing significant funding for a registrational trial indicates a major strategic move that could enhance the company's market position and investor sentiment.

Serina Therapeutics reported second quarter 2026 financial results and provided business updates. Quarterly earnings releases can shift near-term stock sentiment but rarely redefine company trajectory.

Serina Therapeutics completed enrollment and dosing in cohort 1 of its registrational trial for SER-252 in advanced Parkinson’s disease. Completion of initial cohort enrollment advances the lead Parkinson’s candidate through a key registrational study.

Serina Therapeutics completed sentinel dosing in Cohort 1 of its Phase 1b registrational trial for SER-252 in advanced Parkinson’s disease. Early-stage trial milestone advances Parkinson’s drug candidate but remains preliminary without immediate commercial effects.

Gannet BioChem and Serina Therapeutics enter development partnership supporting SER-252 program. Development partnership advances SER-252 without evidence of immediate financial or market transformation.

Serina Therapeutics, Inc. (SER) reported first quarter 2026 financial results and provided business updates. Quarterly financial results and business updates affect key financial performance metrics and investor sentiment.

Serina Therapeutics, Inc. has initiated an inducement plan that grants stock options to new employees as part of its strategy to attract talent. This plan is designed to incentivize new hires and align their interests with the company's long-term goals. The stock options will vest over a specified period, encouraging employee retention and commitment to the company's success. The inducement plan may enhance employee retention and motivation, potentially impacting operational effectiveness and market sentiment.

Serina Therapeutics, Inc. (SER) announces NYSE American acceptance of its continued listing compliance plan, enabling the company to maintain its listing while addressing deficiencies in stockholders' equity, market value of listed securities, and total assets plus revenue. Avoiding delisting preserves trading liquidity and investor access, significantly enhancing SER's market performance and strategic flexibility.

Serina Therapeutics, Inc. (SER) reported full year 2025 financial results and recent business highlights. Annual financial results and business highlights moderately influence financial performance and investor sentiment without transformative changes.

Serina Therapeutics secures up to $30 million in private placement funding to advance the registrational trial of SER-252 for advanced Parkinson’s disease. Securing $30 million enables pivotal registrational trial advancement for SER-252, positioning Serina for potential Parkinson's approval and market entry.

Serina Therapeutics dosed the first patient in its Phase 1b registrational trial of SER-252 for advanced Parkinson’s Disease. Dosing the first patient in a Phase 1b registrational trial marks a major clinical milestone advancing SER-252 toward potential approval for advanced Parkinson’s Disease.

Serina Therapeutics enrolled the first patient in its Phase 1b registrational trial of SER-252 for advanced Parkinson's disease. First patient enrollment in a Phase 1b registrational trial advances SER-252 toward potential approval, boosting pipeline progress and investor sentiment.

Registration is now open for Tribe Public’s CEO presentation and Q&A webinar event featuring Serina Therapeutics, Inc. (SER). The event aims to provide insights into the company's strategies and future plans, allowing participants to engage directly with the CEO. This opportunity is expected to enhance investor relations and provide clarity on the company's direction. The webinar may influence investor sentiment and provide insights into the company's future strategies, but its overall impact is expected to be limited.

Serina Therapeutics, Inc. has received FDA clearance for its Investigational New Drug (IND) application for SER-252, a treatment aimed at advanced Parkinson’s disease. This marks a significant step forward in the company's efforts to develop therapies for this debilitating condition, potentially offering new hope for patients. FDA clearance for SER-252 represents a major strategic move that could significantly alter the company's trajectory and investor sentiment.

Serina Therapeutics, Inc. has received a deficiency notification from the NYSE regarding its shareholders' equity. The notification indicates that the company's equity has fallen below the minimum requirement set by the exchange. Serina is now required to submit a plan to address this deficiency and regain compliance with NYSE listing standards. The NYSE notification may affect investor sentiment and financial performance but does not fundamentally alter the company's trajectory.

Serina Therapeutics, Inc. has appointed Dr. Joshua Thomas as Vice President and Head of Chemistry, aiming to enhance its leadership team. Dr. Thomas brings extensive experience in drug discovery and development, having previously held senior roles at various biotech companies. His expertise is expected to strengthen Serina's capabilities in advancing its therapeutic programs. The appointment of a seasoned professional like Dr. Thomas is likely to positively influence product innovation and operational efficiency.

Serina Therapeutics, Inc. has submitted a complete response to the FDA regarding the clinical hold letter for its SER-252 program. This submission aims to address the concerns raised by the FDA, which had previously halted the clinical trials for SER-252, a treatment for certain medical conditions. The company is optimistic about resuming the program and advancing its development. The response to the FDA's clinical hold is a significant step that could impact the future of the SER-252 program and the company's market position.

Serina Therapeutics, Inc. reported its financial results for the third quarter of 2025, highlighting key business developments and financial metrics. The company showcased progress in its product pipeline and strategic initiatives aimed at enhancing market position. Financial performance indicators reflected ongoing efforts to drive growth and innovation within the therapeutic landscape. Financial results and business highlights indicate moderate influence on the company's performance and market positioning.

Serina Therapeutics, Inc. provided an update on its SER-252 program, detailing progress in regulatory submissions and ongoing clinical trials. The company is focused on advancing its therapeutic candidate for treating various conditions, aiming to meet regulatory requirements and timelines. This update highlights Serina's commitment to its development pipeline and potential market entry. Regulatory updates and progress in clinical trials are likely to significantly impact the company's future performance and investor sentiment.

Serina Therapeutics, Inc. has launched an enhanced corporate communications platform aimed at improving engagement with patients, clinicians, and investors. This initiative is designed to facilitate better information sharing and strengthen relationships across its stakeholder base, reflecting the company's commitment to transparency and collaboration in its operations. The new communications platform may moderately influence engagement and sentiment but is not expected to drastically change the company's trajectory.

Serina Therapeutics, Inc. has secured its first $5 million funding tranche to advance the registrational trial of SER-252, a treatment aimed at Parkinson’s disease. This funding is intended to support the clinical development of SER-252, which is designed to address unmet needs in the treatment of this neurodegenerative disorder. Securing funding for a registrational trial indicates significant progress in product development that could enhance the company's market position.

Serina Therapeutics, Inc. announced that feedback from the FDA supports the design of a registrational trial for SER-252, aimed at treating advanced Parkinson’s Disease, under the 505(b)(2) NDA pathway. This regulatory pathway allows for a streamlined approval process, potentially expediting the development of SER-252. FDA support for the trial design indicates significant progress in the development of SER-252, which could enhance the company's market position.

Serina Therapeutics, Inc. reported its financial results for the second quarter of 2025, highlighting key business developments and financial metrics. The company showcased progress in its product pipeline and strategic initiatives aimed at enhancing growth and market presence. Financial performance indicators, including revenue and expenses, were detailed, reflecting the company's operational status and future outlook. Financial results and business highlights indicate moderate influence on Serina's performance and market positioning.

Serina Therapeutics, Inc. has advanced its investigational drug POZ-VMAT2i into development for treating Tardive Dyskinesia (TD), a movement disorder often caused by long-term use of antipsychotic medications. The company aims to address the unmet medical need for effective TD treatments, as current options are limited and often inadequate. This development marks a significant step in Serina's pipeline and reflects its commitment to improving patient outcomes in neuropsychiatric conditions. Advancing POZ-VMAT2i into development for Tardive Dyskinesia represents a significant strategic move that could enhance Serina's market position and investor sentiment.

Serina Therapeutics, Inc. announced that CEO Steve Ledger will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29, 2025. The company is focused on developing its proprietary POZ Platform™ for drug optimization, targeting neurological diseases and other indications. Serina is based in Huntsville, Alabama, and aims to enhance the efficacy and safety of various therapeutic modalities. The release includes cautionary forward-looking statements regarding the uncertainties in research and development, regulatory approvals, and potential market success. Participation in a significant biotechnology conference may enhance visibility and investor interest, impacting future performance.

Serina Therapeutics, Inc. will present at the FORCE Family Office investor webinar on June 26, 2025, where CEO Steve Ledger will discuss the impact of advanced Parkinson’s disease and the limitations of current treatments. The focus will be on Serina's drug candidate SER-252, designed for continuous dopaminergic stimulation to improve symptom control. The webinar will also highlight the advantages of Serina’s POZ Platform™ for drug optimization. Attendees can submit questions during the event. The presentation of SER-252 and the POZ Platform™ could significantly influence Serina's market position and investor sentiment regarding Parkinson's treatment.

Serina Therapeutics congratulates Juvenescence Ltd. on closing the first tranche of its $150 million Series B funding, totaling $76 million, and forming a strategic partnership with M42. This partnership aims to establish a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with advanced clinical infrastructure. Juvenescence's investment supports its mission to develop therapies for age-related diseases, while Serina benefits from its association with Juvenescence, enhancing its drug optimization technology. The strategic partnership and significant funding are likely to accelerate Serina's development efforts and enhance its market position.

Serina Therapeutics, Inc. congratulates Juvenescence Ltd. on securing $150 million in Series B funding and forming a strategic partnership with M42. This funding aims to accelerate the development of Juvenescence's innovative therapies focused on aging and age-related diseases, enhancing their market position and research capabilities. The funding and partnership could positively influence Serina's competitive positioning and market sentiment in the biotechnology sector.

Serina Therapeutics, Inc. has appointed Stephen Brannan, M.D. to its Board of Directors. Dr. Brannan brings extensive experience in the biopharmaceutical industry, having held various leadership roles and contributed to the development of multiple drug candidates. His expertise is expected to enhance the company's strategic direction and operational capabilities. The appointment of a seasoned professional like Dr. Brannan may positively influence Serina's strategic initiatives and operational effectiveness.